A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia (Q83015673)
Jump to navigation
Jump to search
scientific article published on 29 March 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia |
scientific article published on 29 March 2006 |
Statements
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia (English)
Francis Giles
Stefan Faderl
Norbert Vey
Judy Karp
Gail Roboz
Khuda Dan Khan
Maureen Cooper
Syed Fazl Ali Bilgrami
Augustin Ferrant
Simon Daenen
Verena Karsten
Ann Cahill
Hagop Kantarjian
Susan O'Brien
Eric Feldman
29 March 2006